212 related articles for article (PubMed ID: 17565739)
1. Increased expression of the inflammatory protein YKL-40 in precancers of the breast.
Qin W; Zhu W; Schlatter L; Miick R; Loy TS; Atasoy U; Hewett JE; Sauter ER
Int J Cancer; 2007 Oct; 121(7):1536-42. PubMed ID: 17565739
[TBL] [Abstract][Full Text] [Related]
2. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk.
Sauter ER; Lininger J; Magklara A; Hewett JE; Diamandis EP
Int J Cancer; 2004 Feb; 108(4):588-91. PubMed ID: 14696124
[TBL] [Abstract][Full Text] [Related]
3. Increased shedding of soluble fragments of P-cadherin in nipple aspirate fluids from women with breast cancer.
Mannello F; Tonti GA; Medda V; Pederzoli A; Sauter ER
Cancer Sci; 2008 Nov; 99(11):2160-9. PubMed ID: 18811693
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.
Kim SH; Das K; Noreen S; Coffman F; Hameed M
World J Surg Oncol; 2007 Feb; 5():17. PubMed ID: 17286869
[TBL] [Abstract][Full Text] [Related]
5. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.
Yamac D; Ozturk B; Coskun U; Tekin E; Sancak B; Yildiz R; Atalay C
Adv Ther; 2008 Aug; 25(8):801-9. PubMed ID: 18670741
[TBL] [Abstract][Full Text] [Related]
6. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
Jensen BV; Johansen JS; Price PA
Clin Cancer Res; 2003 Oct; 9(12):4423-34. PubMed ID: 14555515
[TBL] [Abstract][Full Text] [Related]
7. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
[TBL] [Abstract][Full Text] [Related]
8. Leptin expression in breast nipple aspirate fluid (NAF) and serum is influenced by body mass index (BMI) but not by the presence of breast cancer.
Sauter ER; Garofalo C; Hewett J; Hewett JE; Morelli C; Surmacz E
Horm Metab Res; 2004 May; 36(5):336-40. PubMed ID: 15156414
[TBL] [Abstract][Full Text] [Related]
9. Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer.
Sauter ER; Tichansky DS; Chervoneva I; Diamandis EP
Environ Health Perspect; 2002 Mar; 110(3):241-6. PubMed ID: 11882474
[TBL] [Abstract][Full Text] [Related]
10. YKL-40 expression in benign and malignant lesions of the breast: a methodologic study.
Roslind A; Johansen JS; Junker N; Nielsen DL; Dzaferi H; Price PA; Balslev E
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):371-81. PubMed ID: 18091378
[TBL] [Abstract][Full Text] [Related]
11. Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,496 subjects at risk of colorectal cancer.
Johansen JS; Christensen IJ; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Brünner N; Nielsen HJ
Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):621-6. PubMed ID: 25597749
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
[TBL] [Abstract][Full Text] [Related]
13. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer.
Roslind A; Knoop AS; Jensen MB; Johansen JS; Nielsen DL; Price PA; Balslev E
Breast Cancer Res Treat; 2008 Nov; 112(2):275-85. PubMed ID: 18157633
[TBL] [Abstract][Full Text] [Related]
14. Early detection and prognosis of ovarian cancer using serum YKL-40.
Dupont J; Tanwar MK; Thaler HT; Fleisher M; Kauff N; Hensley ML; Sabbatini P; Anderson S; Aghajanian C; Holland EC; Spriggs DR
J Clin Oncol; 2004 Aug; 22(16):3330-9. PubMed ID: 15310777
[TBL] [Abstract][Full Text] [Related]
15. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.
Kucur M; Isman FK; Balci C; Onal B; Hacibekiroglu M; Ozkan F; Ozkan A
Urol Oncol; 2008; 26(1):47-52. PubMed ID: 18190830
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
[TBL] [Abstract][Full Text] [Related]
17. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid.
Alexander H; Stegner AL; Wagner-Mann C; Du Bois GC; Alexander S; Sauter ER
Clin Cancer Res; 2004 Nov; 10(22):7500-10. PubMed ID: 15569980
[TBL] [Abstract][Full Text] [Related]
18. Nipple aspirate fluid color is associated with breast cancer.
Sauter ER; Winn JN; Dale PS; Wagner-Mann C
Cancer Detect Prev; 2006; 30(4):322-8. PubMed ID: 16963197
[TBL] [Abstract][Full Text] [Related]
19. Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2.
Mannello F; Qin W; Zhu W; Fabbri L; Tonti GA; Sauter ER
Breast Cancer Res Treat; 2008 Sep; 111(2):209-18. PubMed ID: 17932742
[TBL] [Abstract][Full Text] [Related]
20. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma.
Biggar RJ; Johansen JS; Smedby KE; Rostgaard K; Chang ET; Adami HO; Glimelius B; Molin D; Hamilton-Dutoit S; Melbye M; Hjalgrim H
Clin Cancer Res; 2008 Nov; 14(21):6974-8. PubMed ID: 18980992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
